The team, registered with PROSPERO and following PRISMA reporting guidelines, searched PubMed and the China National Knowledge Infrastructure through December 2025, ultimately distilling 106 retrieved records down to six eligible studies. To qualify, research had to involve patients aged sixty or older, measure inflammatory or inflammaging-related biomarkers in blood or skin, and quantify disease severity using validated instruments such as the SCORAD index. The methodological rigor extended to a deliberate sensitivity decision: one study that used squamous cell carcinoma antigen, a keratinocyte proliferation marker, as a laboratory surrogate for disease activity was retained in the primary synthesis but flagged, and its removal was tested to confirm the headline findings did not depend on it.

Statistically, the authors converted reported Pearson and Spearman correlation coefficients into Fisher’s z values, weighted them by sample size, and pooled them using DerSimonian-Laird random-effects models when heterogeneity demanded it. Four biomarker families survived the quantitative synthesis. Total IgE showed a moderate positive correlation with severity, pooled at r = 0.464 across 139 participants, and the estimate strengthened to r = 0.514 with minimal heterogeneity once the surrogate-based study was excluded. Eosinophil counts proved the most stable signal of all, correlating at r = 0.522 with essentially zero heterogeneity, suggesting these granulocytes remain a remarkably reliable barometer of eczema activity even in aged immune systems.

The cytokine story was messier and, arguably, more interesting. Interleukin-4, the canonical Th2 driver of allergic disease, correlated with severity at a pooled r = 0.571, but with a confidence interval stretching from 0.176 to 0.808 and heterogeneity approaching 87 percent. Interleukin-17, representing the Th17 axis, landed at a similar pooled r = 0.566 with nearly identical heterogeneity. In a younger population, such statistical noise might be dismissed as methodological artifact. Here, the authors argue, it may be a genuine biological signal: some elderly patients appear to run a Th2-high profile familiar from pediatric eczema, while others shift toward a Th17-dominant or mixed phenotype, a divergence that could explain why biologic therapies targeting a single pathway produce such variable results in older adults.

To organize this complexity, the researchers proposed a four-stage conceptual framework, explicitly labeled hypothesis-generating rather than proven. The first stage is inflammaging itself: the chronic, low-grade elevation of pro-inflammatory mediators that accompanies immunosenescence. In one cohort of 21 patients, the inflammaging markers IL-6, CXCL1, CCL7, and SELE all correlated significantly with severity, with coefficients between 0.45 and 0.54. The idea is that this systemic inflammatory backdrop lowers the threshold for skin immune homeostasis, priming the tissue to overreact to triggers that a younger immune system would quietly tolerate. Inflammaging, in this model, is not merely a bystander but the catalyst that sets the entire cascade in motion.

The second stage describes an abnormally amplified Th2 response operating within that inflamed terrain. Across six studies and 243 patients, the Th2 cluster, including IL-4, TSLP, TARC, CCL26, eosinophils, and total IgE, showed correlations ranging from 0.10 to 0.79, with ten of twelve individual associations reaching significance. The internal inconsistency is telling. Eosinophils tracked severity faithfully, while IgE performed erratically, echoing observations that late-onset atopic dermatitis frequently presents as an intrinsic variant with lower IgE and atypical inflammatory profiles. Some patients may retain the classic Th2 signature; others may drift toward what the authors call a Th2-evolved pattern, in which IL-4 signals wane and cytokines like IL-13 or IL-31 take over the driver’s seat.

Stage three introduces the Th17 axis as an aberrant intruder. In healthy immune regulation, Th17 activity is held in check by counterbalancing networks, but aging is known to disturb the Th17/Treg balance. The pooled data, drawing on IL-17, IL-17A, IL-17C, IL-22, and CCL20 across three studies, showed moderate-to-strong correlations with severity, with individual coefficients spanning 0.32 to 0.76. The authors hypothesize that weakened regulatory constraints in the aged immune system allow this normally secondary pathway to run amok in a subset of patients, producing a Th17-high endophenotype. If validated in prospective, molecularly stratified cohorts, this could reshape therapeutic thinking, since IL-17 and IL-23 blockers may benefit one subgroup of elderly patients while doing little for another.

The final stage is where the disease becomes self-sustaining. Tissue remodeling markers, matrix metalloproteinase 12, ezrin, and cadherin 3, showed the strongest correlations with severity of any group, ranging from 0.56 to 0.59, all highly significant. MMP12 in particular sits at the junction between immune inflammation and structural collapse: its upregulation drives extracellular matrix degradation and disrupts keratinocyte differentiation, breaching the skin barrier and feeding the very inflammation that produced it. This inflammation-barrier destruction vicious cycle, the authors contend, is the molecular engine of chronicity, explaining the refractory, non-healing lesions that clinicians so often see in older patients regardless of which immune pathway dominates upstream.

The clinical implications are significant. Treatment decisions in elderly eczema, the authors emphasize, must weigh biological age, frailty, and immunosenescence status rather than severity scores alone. Age-specific evidence for biologics remains thin, though promising case data exist for dupilumab, the IL-4/IL-13 blocker, even in patients over eighty. If biomarker-defined subgroups can be validated, the four-stage framework could eventually guide which older patients get Th2-targeted agents, which need Th17 coverage, and which require barrier-restoration strategies to break the remodeling cycle. That vision, however, remains aspirational.

The authors are candid about the limits of their evidence. Only four biomarkers were formally pooled; most contributed just two to four effect sizes, too few for funnel plots, Egger’s tests, or meaningful meta-regression. The included studies were overwhelmingly cross-sectional, so causality and temporal sequence cannot be established, and the search was confined to two databases. Small samples, inconsistent confounder control, and methodological variation likely inflate the heterogeneity figures. The four-stage model is therefore a scaffold for future research, not a settled pathway. Even so, the message is hard to ignore: as populations age worldwide, eczema in the elderly is rising, and it may demand its own immunology, its own biomarkers, and its own playbook, rather than a pediatric disease map stretched over older skin.

Subject of Research: Immune axis imbalance and inflammaging mechanisms underlying chronic atopic dermatitis in elderly patients

Article Title: Inflammatory Aging‐Driven Immune Axis Imbalance and the Mechanisms of Chronicity in Elderly Atopic Dermatitis: A Systematic Review and Meta‐Analysis

Article References: Wu, N., Li, Y., Wang, X., Wu, Y., & Yin, W. (2026). Inflammatory Aging‐Driven Immune Axis Imbalance and the Mechanisms of Chronicity in Elderly Atopic Dermatitis: A Systematic Review and Meta‐Analysis. Immunity, Inflammation and Disease, 14(9), Article e70528. https://doi.org/10.1002/iid3.70528

Image Credits: AI Generated

DOI: 10.1002/iid3.70528

Keywords: atopic dermatitis, inflammaging, immunosenescence, meta-analysis, Th2 response, Th17 axis, IL-17, IL-4, eosinophils, MMP12, skin barrier, elderly patients